The trial is evaluating EB103, which is a CD19-redirected ARTEMIS® T-cell therapy, in adult patients (aged 18 and older) with ...

The analysts are supporting the company’s potential in the broader mental health sector, demonstrating the transformative ...

Highlights from the 2025 Global Equine Endocrinology Symposium included never-before-presented study results on insulin ...

Several oral abstracts presented at the American Society of Clinical Oncology’s annual meeting highlight ongoing research of Keytruda, Opdivo, Tecentriq and more in skin cancer.

Reducing the length of immunotherapy treatment for an advanced skin cancer did not significantly diminish disease control ...

Specialty televisits remain common in the Veterans Health Administration following the COVID-19 pandemic, suggesting they will remain an important ongoing care modality for many patients.

IVMED-85 is a preservative-free, non-atropine daily drop that slows myopia progression by strengthening scleral and corneal ...

Discover the major highlights from ASCO 2025, according to researchers and drug developers who attended the convention.

At ASCO, researchers presented results of Phase I trials evaluating combinations of KRAS G12C inhibitors, EGFR inhibitors, and chemotherapy in colorectal cancer.

Bayer’s Vividion Therapeutics has secured the global rights from its partner Roche to the only Werner helicase (WRN) ...

When executed with precision and transparency, ECAs can enhance trial efficiency, expand access and support evidence—while ...

An annual review of clinical trials for Alzheimer's disease highlights a growing number of active trials—and drugs—in the ...